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Introduction: Ovarian cancer (OvCa) is the most lethal gynecologic malignancy in the
United States because of chemoresistant recurrent disease. Our objective was to inves-
tigate the efficacy of inhibiting the Notch pathway with a γ-secretase inhibitor (GSI) in an
OvCa patient-derived xenograft model as a single agent therapy and in combination with
standard chemotherapy.
Methods: Immunocompromised mice bearing xenografts derived from clinically platinum-
sensitive human ovarian serous carcinomas were treated with vehicle, GSI (MRK-003)
alone, paclitaxel and carboplatin (P/C) alone, or the combination of GSI and P/C. Mice bear-
ing platinum-resistant xenografts were given GSI with or without paclitaxel. Gene transcript
levels of the Notch pathway target Hes1 were analyzed using RT-PCR. Notch1 and Notch3
protein levels were evaluated.TheWilcoxon rank-sum test was used to assess significance
between the different treatment groups.
Results: Expression of Notch1 and 3 was variable. GSI alone decreased tumor growth
in two of three platinum-sensitive ovarian tumors (p<0.05), as well as in one of three
platinum-sensitive tumors (p=0.04). The combination of GSI and paclitaxel was signifi-
cantly more effective than GSI alone and paclitaxel alone in all platinum-resistant ovarian
tumors (all p<0.05).The addition of GSI did not alter the effect of P/C in platinum-sensitive
tumors. Interestingly, although the response of each tumor to chronic GSI exposure did not
correlate with its endogenous level of Notch expression, GSI did negatively affect Notch
signaling in an acute setting.
Conclusion: Inhibiting the Notch signaling cascade with a GSI reduces primary human
xenograft growth in vivo. GSI synergized with conventional cytotoxic chemotherapy only
in the platinum-resistant OvCa models with single agent paclitaxel. These findings sug-
gest inhibition of the Notch pathway in concert with taxane therapy may hold promise for
treatment of platinum-resistant OvCa.
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INTRODUCTION
Ovarian cancer (OvCa) represents the second most common, and
most lethal gynecologic malignancy in the United States. By the
end of 2013, it is estimated that over 22,000 women will have been
diagnosed with OvCa, and more than 15,000 patients will have
succumbed to the disease (1). The high death rate is due in part to
the fact that the majority of patients present with advanced stage
disease possibly due to a lack of screening strategies that effec-
tively detect the cancer in early stages. The most common subtype
is high-grade serous carcinoma (70%), followed by endometrioid
and clear cell variants (2). Despite the histologic variation, the
current treatment regimen includes cytoreductive surgery as well
as six cycles of taxane and platinum-based chemotherapy deliv-
ered IV or IP (3, 4). While 70–80% of patients respond to this
first-line chemotherapy, recurrences occur frequently and a signif-
icant majority of those patients develop chemoresistant disease (5,
6). The overall prognosis of patients diagnosed with OvCa there-
fore remains poor, with a 5-year survival rate of approximately
50% (4). Insights into key molecular pathways that are overex-
pressed in OvCa and contribute to tumor progression, recurrence,
and chemoresistance may lead to novel therapies that can improve
the treatment strategies for these women.
The Notch signaling cascade has been implicated in numer-
ous malignancies (7–11) and is one of the most altered pathways
in serous OvCa (2). Notch signaling is involved in the regulation
of proliferation, differentiation, cell fate, and survival and plays an
important role in embryonic development as well as in self-renewal
of adult stem/progenitor cells (12–14). Activation of the Notch
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signaling cascade occurs through binding of one of four Notch
receptors (Notch1–4) with one of its ligands (Jagged and Delta-
like) on a neighboring cell. Sequential proteolytic cleavage of the
Notch receptor by a disintegrin and metalloprotease (ADAM) and
γ-secretase leads to the release of the Notch intracellular domain
(NICD). This active fragment subsequently translocates to the
nucleus, where it activates transcription of target genes including
members of the HES and HEY families (12, 15).
Recent studies have demonstrated expression of the Notch
pathway in many malignancies including breast, intestinal, pan-
creatic, brain, and OvCa (10, 16–21). Genomic analyses of ovarian
carcinomas as part of The Cancer Genome Atlas (TCGA) Project
showed alteration of Notch signaling in 22% of analyzed tumors
(2). In addition, Notch1 and Notch3 RNA transcript and pro-
tein are highly expressed in ovarian carcinomas (22–27) and ele-
vated expression correlates with resistance to chemotherapy and
decreased survival (28–30). Investigators have hypothesized that
Notch signaling may promote the activity of a tumor-initiating cell
population that can sustain the growth of ovarian tumors despite
cytotoxic therapies that halt the progression of actively proliferat-
ing cancer cells (31–33). While this hypothesis is controversial, it
would provide rationale for combining Notch pathway inhibition
with conventional cytotoxic therapy.
Targeting of the Notch pathway is currently being investigated
in a variety of cancers, with γ-secretase inhibitors (GSIs) being the
most widely used Notch inhibitors (34, 35). Few phase I and II
clinical trials have reported GSI anti-tumor activity though these
studies have included only a few women with OvCa. Previous
pre-clinical studies have shown that inhibition of Notch signal-
ing blocks the growth of both OvCa cell lines in vitro and cell
line-derived xenografts in vivo (36–38). In addition to inhibition
of cell proliferation and induction of cell death, treatment with
GSI is associated with an increased sensitivity of OvCa cell lines
to platinum therapy (39) supporting the concept that treatment
with Notch antagonists may be relevant in a recurrent disease
setting (28).
In the current study, we analyzed the contribution of the Notch
pathway to the pathobiology of serous OvCa. We assessed the
expression of specific members of the Notch family and tested the
anti-tumor activity of the GSI MRK-003 against patient-derived
xenografts (PDXs) generated from serous carcinomas of the ovary
or peritoneum. The pre-clinical efficacy of MRK-003 has been
determined in several human cancers (8, 9, 34, 40–43), and we
wanted to assess the effectiveness of this GSI as a single agent and in
combination with standard cytotoxic chemotherapy in a cohort of
clinically platinum-sensitive and resistant ovarian tumors. Treat-
ment of mice harboring the ovarian tumor xenografts with MRK-
003 resulted in reduced tumor growth in a subset of experiments.
Combination cytotoxic chemotherapy and GSI demonstrated syn-
ergistic activity only in those platinum-resistant tumors suggesting
Notch pathway inhibition may be more effective in the recurrent
and refractory setting.
MATERIALS AND METHODS
GENERATION AND PROPAGATION OF OVARIAN CANCER XENOGRAFTS
Our PDX model utilizing primary human ovarian tumors has
been described previously (44). Briefly, excess serous OvCa tissue
or ascites was obtained at the time of surgery from patients
who had given informed consent to participate in an Institu-
tional Review Board approved tissue collection protocol. Follow-
ing enzymatic processing, tumor-derived single-cell suspensions
were depleted of hematopoietic and endothelial cells, resuspended
in PBS, mixed with Matrigel (1:1), and injected subcutaneously
(s.c.) in female NOD/SCID mice. The range of cells injected
was 7.5× 105 to 1.5× 106 in each animal. Tumor formation in
the injected animals was regularly monitored, and tumors were
harvested from euthanized animals when they reached a diame-
ter of 1–2 cm. The harvested xenografts were then enzymatically
processed, depleted of H-2Kd positive mouse cells, and injected
s.c. into NOD/SCID mice as described above. Using this trans-
plantation system, cohorts of 15–40 mice injected with OvCa cells
derived from a single patient were generated and subsequently
used to perform treatment experiments.
IMMUNOHISTOCHEMICAL ANALYSIS
Notch1 and Notch3 protein expression in formaldehyde fixed and
paraffin embedded sections of primary and xenograft ovarian
tumors were analyzed by immunohistochemistry (IHC) using a
mouse monoclonal anti-Notch1 antibody (Novus Biologicals) or
a rabbit polyclonal anti-Notch3 antibody (Abgent). Non-specific
binding of antibody was blocked by either the Vector Labora-
tories M.O.M. kit (in the case of Notch1) or 5% normal goat
serum in PBS with 0.1% Triton X (Notch3) followed by incubation
with the relevant primary antibody and the appropriate biotiny-
lated secondary antibody. Subsequent treatment with Vectas-
tain ABC reagents (Vector Laboratories), visualization with 3,3′-
diaminobenzidine chromogen (DAB, Dako), and counterstaining
with hematoxylin were performed.
IMMUNOBLOTTING
Whole cell lysates were prepared from frozen xenograft samples or
cell lines using Mammalian Protein Extraction Reagent (Thermo
Scientific) lysis buffer supplemented with inhibitors of endoge-
nous protease, kinase, and phosphatase activity (all obtained from
Sigma-Aldrich). Twenty micrograms of protein from each sample
were separated on 7.5 or 10% polyacrylamide gels and trans-
ferred to a PVDF membrane. Following transfer, membranes
were blocked with 5% milk in 1× TBS, 0.1% Tween-20 (TBST)
and incubated in diluted (1:1000) primary antibody overnight,
according to the manufacturer’s recommendations. Primary anti-
bodies used were a rabbit monoclonal anti-Notch1 antibody,
a rabbit monoclonal anti-cleaved Notch1 (Val1744) antibody,
and a rabbit monoclonal anti-Notch3 antibody (Cell Signaling).
Membranes were then incubated with a horseradish peroxidase
(HRP) conjugated goat anti-rabbit secondary antibody (Santa
Cruz Biotechnology) and developed using a chemiluminescent
detection reagent obtained from GE Healthcare Life Sciences.
Equivalent protein loading was verified by stripping the blots and
re-probing with a mouse anti-Pan-Actin antibody (NeoMarkers).
CELL CULTURE AND IN VITRO TREATMENT WITH MRK-003
The OVCAR3 and SKOV3 human OvCa cell lines were purchased
from ATCC. For MRK-003 dose response experiments, equal num-
bers of OVCAR3 or SKOV3 cells were plated and serum-starved
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overnight in growth medium containing 1% FBS. Cells were incu-
bated in triplicate (OVCAR3) or quadruplicate (SKOV3) with
either 0, 1, 5, or 10µM MRK-003. After 48 h, cells were harvested
and quantified. Subsequently, OVCAR3 and SKOV3 cells were
treated with either the relevant MRK-003 IC50 or vehicle control
only. Cells were harvested 6 h after administration of MRK-003,
and cell pellets were frozen for immunoblotting and quantitative
PCR analyses.
TREATMENT OF MICE BEARING SEROUS OVARIAN CANCER
XENOGRAFTS
All xenograft tumors were generated from prospectively con-
sented patients, and their clinical response to platinum-based
adjuvant therapy was used to stratify the cohorts of mice bear-
ing serous OvCa xenografts. Tumors collected from patients who
did not develop resurgence of their serous OvCa for longer than
6 months were labeled platinum-sensitive. Those tumors derived
from patients who developed recurrence<6 months were deemed
to be platinum-resistant. Tumor growth in mice was monitored
regularly, and treatment regimens were started when tumor vol-
umes were 200–400 mm3. Mice were then randomly divided into
four cohorts of five to seven mice each. Mice bearing xenografts
derived from clinically platinum-sensitive OvCa were random-
ized to treatment with either MRK-003 alone (300 mg/kg in
0.5% methylcellulose) once weekly by oral gavage, paclitaxel and
carboplatin (P/C) alone, MRK-003 with P/C, or vehicles of all
three drugs. Mice harboring clinically platinum-resistant ovarian
tumors were treated with either MRK-003 alone, paclitaxel alone,
MRK-003 with paclitaxel, or vehicles of MRK-003 and paclitaxel.
Paclitaxel (15 mg/kg), carboplatin (50 mg/kg), and their appro-
priate vehicles (Cremophor:ethanol and saline, respectively) were
given once weekly by intraperitoneal (i.p.) injection. Tumor vol-
umes were determined every 3–4 days, and mice were weighed
weekly. The length of experiments was determined by the individ-
ual tumor growth patterns in the vehicle setting so that all arms of
experiments could be terminated at one time to decrease biologic
variability. At the end of each treatment experiment, mice were
euthanized and tumors were harvested. One portion of each tumor
was snap frozen, and a second portion was fixed in formaldehyde
and embedded in paraffin.
In order to study the acute effect of MRK-003 treatment
on Notch pathway activation, mice harboring primary OvCa
xenografts were given one dose of MRK-003 or vehicle. Tumors
were harvested 6, 24, or 48 h after treatment, and portions were
snap frozen as well as fixed in formaldehyde and embedded in
paraffin.
QUANTITATIVE PCR ANALYSIS
RNA was isolated from frozen xenograft tissue or cell pel-
lets using the GenElute mammalian RNA extraction kit
and converted to cDNA (SuperScript VILO, Life Tech-
nologies). Quantitative real-time PCR (qPCR) analysis was
performed with SsoAdvanced SYBR Green Supermix (Bio-
Rad Laboratories) and primers specific for human Hes1
(forward: 5′-ATTCCTCGTCCCCGGTGGCT-3′; reverse: 5′-
TCCAGCTTGGAATGCCGCGAG-3′) and β-actin (forward: 5′-
GAGCACAGAGCCTCGCCTTT-3′; reverse: 5′-TCATCATCCATG
GTGAGCTGG-3′). For each analyzed sample, relative expression
of Hes1 mRNA normalized to β-actin mRNA was determined as
previously described (45).
STATISTICAL ANALYSIS
Because of the non-normal distribution of tumor volumes, non-
parametric Wilcoxon rank-sum tests were carried out to deter-
mine whether the observed differences in tumor volume between
the groups in each treatment experiment were statistically sig-
nificant. All analyses were done using Stata version 11.1 soft-
ware (StataCorp LP), and a p-value of <0.05 was considered
statistically significant.
RESULTS
EXPRESSION OF Notch1 AND Notch3 IN SEROUS OVARIAN CANCER
Notch1 and Notch3 protein expression in both the primary human
papillary serous OvCas that were utilized in the current study
(OV1–OV7; see Table 1) and in xenografts derived from these
patient samples were assessed by IHC (Figures 1A,C). Addition-
ally, Notch1 and Notch3 expression in the same xenografts was
analyzed by immunoblotting (Figures 1B,D). Variable expression
of both Notch1 and Notch3 was found in all primary tumors and
xenografts. IHC revealed that Notch protein levels were consis-
tent between each primary tumor and its corresponding xenograft
tumor and largely correlated with the protein level detected by
immunoblotting.
EFFECT OF γ-SECRETASE INHIBITION ON OVCAR3 AND SKOV3 CELL
PROLIFERATION AND CLEAVED Notch1 AND Hes1 LEVELS
OVCAR3 and SKOV3 cells were treated with 1, 5, and 10µM
MRK-003. After an incubation period of 48 h, a dose-dependent
Table 1 | Clinical characteristics of patients whose tumors were analyzed in this study.
Patient Age at diagnosis Stage Grade Progression free Overall survival Current status
(years) survival (months) (months)
OV1 38.3 IV 3 34.1 57.9 Alive
OV2 62.7 IIIC 3 23.9 37.6 Deceased
OV3 60.7 IIIC 3 18.5 24.1 Deceased
OV4 50.8 IIIC 3 22.4 28.9 Alive
OV5 68.4 IIIC 3 7.9 7.9 Deceased
OV6 54.8 III ND 7.1 10.3 Deceased
OV7 90.5 Unstaged ND 4.9 6.5 Deceased
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FIGURE 1 |Variable expression of Notch1 and Notch3 in ovarian cancer
specimens. (A,C) Immunohistochemical analyses of Notch1 and Notch3
expression was carried out on xenograft tumors generated from all seven
tumors that were subsequently used for treatment studies (OV1–OV7), as
well as on paired primary tissue samples when available (OV1–OV5).
Representative images of Notch1 (A) and Notch3 (C) immunostaining are
shown. (B,D)Western blotting was performed to analyze expression of
Notch1 (B) and Notch3 (D) in xenografts derived from primary human serous
ovarian cancers (OV1–OV7). Uncleaved, inactivated Notch1 and Notch3 as well
as cleaved activated Notch1 and Notch3 are shown. An anti-Pan-Actin
antibody was used to confirm equivalent loading of samples. The HCC1187
and SKOV3 cell lines were used as a negative control (−Cx) for Notch1 and
Notch3, respectively. The MCF-7 cell line was used as a positive control (+Cx)
for both Notch1 and Notch3.
reduction in OVCAR3 and SKOV3 cell counts was found
compared to cells incubated with medium only (see Figure 2A).
Subsequently, OVCAR3 and SKOV3 cells were treated with either
MRK-003 at the relevant IC50 (5µM for OVCAR3, 10µM for
SKOV3) or vehicle control for 6 h and then harvested. The impact
of MRK-003 on Notch signaling was assessed by immunoblotting
analysis of γ-secretase-cleaved Notch1 levels and qPCR analysis of
target gene Hes1 expression. We observed both a strong reduction
in cleaved Notch1 protein levels as well as a marked decrease in
Hes1 gene expression relative to the vehicle treated control in both
cell lines following treatment with MRK-003 (see Figures 2B,C).
IMPACT OF MRK-003 IN VIVO TREATMENT ON Hes1 EXPRESSION
Our in vitro data suggest that MRK-003 specifically targets the
Notch pathway in OvCa cell lines. To extend these findings, we
assessed the effect of MRK-003 on Notch signaling in PDXs.
OvCa xenografts were harvested from mice 6, 24, or 48 h after
administration of a single dose of MRK-003 or vehicle con-
trol and expression of the Notch target gene Hes1 was ana-
lyzed by qPCR. In all analyzed xenografts, a 30–70% decrease
in Hes1 mRNA levels, relative to levels in vehicle treated con-
trols, was observed after exposure to MRK-003. Figure 3 is
a representative example of these analyses and illustrates the
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FIGURE 2 |The γ-secretase inhibitor MRK-003 inhibits OVCAR3 and
SKOV3 cell proliferation and decreases NICD1 and Hes1. (A) In vitro
treatment of OVCAR3 and SKOV3 cells with MRK-003 leads to a
dose-dependent reduction of cell proliferation. Cells were incubated with
increasing concentrations (0–10µM) of MRK-003 for 48 h in medium
containing 1% FBS. OVCAR3 cells were treated in triplicate, and SKOV3
cells were treated in quadruplicate. Average relative changes in cell
numbers are shown, and error bars represent the standard error of the
mean. (B)Western blotting analysis of OVCAR3 and SKOV3 cells incubated
with 5µM (OVCAR3) or 10µM (SKOV3) MRK-003 for 6 h reveals a marked
decrease in expression of cleaved Notch1 (Val1744). An anti-Pan-Actin
antibody was used to confirm equivalent loading of samples.
Control= cells incubated with medium only. (C) qPCR analysis of Hes1
gene expression in MRK-003 treated OVCAR3 and SKOV3 cells, harvested
6 h post treatment, showed significantly decreased Hes1 transcript levels
compared with cells incubated with medium only. Relative changes in
Hes1 mRNA expression are shown, normalized to expression of
housekeeping gene β-actin.
relative transcript levels of Hes1 in OV5 xenografts collected
6 h after treatment with MRK-003 or vehicle. OV5 was selected
as a representative example as this was a platinum-resistant
tumor that demonstrated a potent synergy with paclitaxel in our
in vivo experiments.
ASSESSMENT OF THE IMPACT OF MRK-003 AS A SINGLE AGENT OR IN
COMBINATION WITH CYTOTOXIC CHEMOTHERAPEUTICS ON OVARIAN
CANCER XENOGRAFTS
The clinical characteristics of the seven patients whose tumors
were used to generate primary xenografts are summarized in
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FIGURE 3 |Treatment with MRK-003 decreases Hes1 expression
in vivo. qPCR analysis of Hes1 gene expression was performed using
xenograft samples collected 6, 24, and 48 h after treatment with MRK-003
or vehicle. Hes1 expression in OV5 xenografts collected 6 h after
administration of MRK-003 (n=2) or vehicle (n=2) is shown. Average
relative changes in Hes1 mRNA expression were determined following
normalization to β-actin expression. Error bars represent the standard error
of the mean.
Table 1. Briefly, all samples were obtained from women with
primarily advanced stage disease, three of whom manifested
platinum-sensitive disease and markedly improved survival com-
pared to the platinum-resistant patients. In three independent
experiments, mice harboring xenografts derived from a platinum-
sensitive tumor were randomized to receive either MRK-003 alone,
P/C alone, the combination of MRK-003 and P/C, or vehicle
alone. We observed a significant reduction in OV3 (p= 0.02) and
OV4 (p< 0.01) PDX growth following administration of MRK-
003 alone, compared with vehicle treated control tumors (see
Figure 4). Treatment with P/C alone significantly decreased tumor
volumes of all three analyzed platinum-sensitive PDXs, and com-
bination therapy with MRK-003 and P/C was not more effective
than treatment with P/C alone (see Figure 4). In Figure 4A, the
combined P/C and MRK-003 arm was truncated early so that
tumor could be harvested for post treatment investigation. No
signs of toxicity were observed in mice receiving MRK-003 and
animal weights remained stable during the course of treatment
(data not shown).
The three primary human platinum-resistant serous ovarian
tumors were also established as PDXs in immunocompromised
mice. In three separate experiments, mice harboring the tumors
were subjected to therapy with either MRK-003 alone, pacli-
taxel alone, MRK-003 in combination with paclitaxel, or vehicle
alone. In all analyzed tumors, enhanced anti-tumor activity was
found in mice treated with the combination of MRK-003 and
paclitaxel, compared with paclitaxel alone and MRK-003 alone
(p< 0.03, see Figure 5). Administration of paclitaxel as a single
agent led to a significant decrease of xenograft growth in only
one of three tumors (OV7, p< 0.01, see Figure 5C). In addition,
MRK-003 monotherapy led to significant tumor growth reduction
of OV5 xenografts, compared with vehicle treatment (p= 0.04,
see Figure 5A). Again, no significant weight loss or other signs of
toxicity were observed in mice treated with MRK-003 (data not
shown).
DISCUSSION
In the current study, we confirm that members of the Notch signal-
ing pathway are expressed in serous OvCa, and GSI-mediated tar-
geting of this pathway leads to anti-proliferative effects in vitro and
anti-tumor activity in vivo. While single agent GSI was tumorstatic
in half of the analyzed PDXs, combination therapy with cytotoxic
chemotherapy led to significant synergistic anti-tumor effects only
in those xenografts originally derived from platinum-resistant
OvCa patients. Collectively, these pilot data support the role of
Notch signaling in OvCa growth particularly in the chemoresistant
setting.
Various studies have detected Notch1 and Notch3 expression
in ovarian tumors by IHC, real-time polymerase chain reaction,
and/or immunoblotting. The results for Notch1 expression via
detection by IHC have been variable and difficult to interpret.
In one study of relative Notch1 expression in benign ovarian tis-
sue and a spectrum of low- to high-grade ovarian carcinomas,
Notch1 was rarely detected in benign tissue and its expression
level correlated with increasing grade and clinical stage of dis-
ease (23). Interestingly, Notch1 was primarily confined to the cell
membrane and the cytoplasm. The direct functional or clinical sig-
nificance of increased cytoplasmic expression in OvCa is unclear
given that cleaved Notch1 migrates to the nucleus and is consid-
ered the active form. In similar immunohistochemical analyses,
no nuclear Notch1 expression was detected suggesting little to no
role for Notch1 in OvCa (46). In contrast, Notch1 nuclear expres-
sion was evident in our cohort of samples but was highly variable
among and within samples. Despite the variation between sam-
ples, however, the intensity of nuclear Notch1 expression in each
primary tumor and its correlate xenografts was stable reinforc-
ing that Notch1 expression remains consistent across subsequent
xenograft generations. These data suggest that protein expression
of Notch1 or 3 does not correlate with response to GSI suggesting
many other molecular inputs must be involved with modulating
response in the platinum-resistant setting.
While Notch1 IHC studies have generated conflicting results,
immunoblotting analyses that have largely focused on Notch1
NICD expression in primary samples and established human
OvCa cell lines are much less controversial. Rose et al. (22) found
abundant levels of cleaved Notch1 in the OVCAR3, SKOV3, and
CaOV3 cell lines as well as in approximately 75% of the pri-
mary OvCa samples analyzed. Consistent with published work
(22, 36), we similarly detected cleaved Notch1 in OvCa cell lines
and primary ovarian tumor samples by immunoblotting. Thus,
in contrast to the collective IHC results, the data to date suggest
that cleaved Notch1 is present in some samples thereby providing
indirect evidence that Notch1 signaling is active in OvCa.
This hypothesis is further bolstered by functional studies that
suggest Notch1 promotes OvCa cell proliferation. In one investi-
gation, stable transfection of A2780 OvCa cells with the Notch1
NICD increased both cell proliferation and the rate of colony
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FIGURE 4 | MRK-003 treatment in vivo inhibits tumor growth in the
majority of analyzed platinum-sensitive ovarian cancers. Three
independent cohorts of mice bearing xenografts derived from clinically
platinum-sensitive serous ovarian cancer were treated with vehicle, MRK-003
alone, paclitaxel/carboplatin (P/C) alone or P/C+MRK-003. A significant
anti-tumor effect of treatment with MRK-003 alone was observed in OV3
(B) and OV4 (C) xenografts (p<0.05). P/C alone and P/C+MRK-003 were
equally effective in significantly reducing tumor growth of OV2 (A), OV3, and
OV4 xenografts (p<0.01). Tumor volumes were measured twice weekly.
Error bars represent the standard error of the mean.
FIGURE 5 | MRK-003 and paclitaxel synergize to inhibit growth of
platinum-resistant ovarian tumors. Three independent cohorts of mice
bearing xenografts derived from clinically platinum-resistant serous ovarian
cancer were randomly divided into four groups. Each group received
vehicle, paclitaxel alone, MRK-003 alone or paclitaxel+MRK-003.
Significantly heightened inhibition of tumor growth was observed upon
combination treatment with paclitaxel+MRK-003, compared with
treatment with either drug alone (p<0.03). Tumors were measured twice
weekly. Error bars represent the standard error of the mean. OV5 (A); OV6
(B); and OV7 (C).
formation (26). Others found that down regulation of γ-secretase
activity reduced Notch1 and Hes1 mRNA and protein in the same
A2780 OvCa cells and this decrease correlated with a decrease in
cell proliferation (36). Since pan inhibition of γ-secretase likely
inhibits activation of all Notch receptors, the observed effects may
not be due to specific disruption of Notch1 signaling. Rose and
colleagues (22) provided more direct evidence of Notch1 involve-
ment in cell proliferation by siRNA-mediated reduction of Notch1
levels. The decrease in Notch1 in response to siRNA correlated
with decreased cell proliferation. Thus, the in vitro data suggest
that Notch1 signaling can influence the biology of OvCa.
Notch3 has also been implicated in the pathology of OvCa as
its expression is evident in a significant number of analyzed OvCa
samples. Unlike Notch1, however, investigators have focused on
nuclear localization of Notch3 as a functional marker of pathway
activation (25, 27, 29, 47). Like Notch1, Notch3 was also expressed
at much lower levels in benign ovarian tissue when compared to
malignant samples (25, 29), and higher expression levels were asso-
ciated with either advanced stage (29) or recurrent disease (28, 48).
At the genomic level, the Notch3 gene was amplified in a cohort of
OvCa samples, as detected by fluorescence in situ hybridization,
and this amplification positively correlated with increased Notch3
protein expression (24). This finding was supported by recent data
from TCGA, which also showed that Notch3 was amplified in
serous ovarian carcinoma (2). Our data support the finding that
cleaved Notch3 is present in primary OvCa samples and likely con-
tributes to the pathology of OvCa (24, 25, 39, 48). Blocking Notch3
signaling by a GSI or a Notch3 specific siRNA reduced cell number
and led to an increase in apoptosis in OVCAR3 and A2780 OvCa
lines (24). Interestingly, the Notch ligand Jagged-1 was abundantly
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expressed in both OvCa cell lines and benign mesothelial cells
derived from tumors (25). Both gene knockdown of Jagged-1 and
transfection of the Notch3 intracellular domain (NICD3) suggest
the existence of a juxtacrine loop that impacts ovarian cell-cell
adhesion and tumor growth (25).
While Notch3 appears to play a role in OvCa cell prolifer-
ation, tumor growth, and metastasis, additional investigations
have implicated Notch signaling in chemoresistance (28, 39,
48). Knockdown of Notch3 sensitizes OvCar3 cells to carbo-
platin (28). Additionally, Notch3 is overexpressed in cisplatin and
cisplatin/paclitaxel-resistant OvCa cell lines and its inactivation
by GSI or siRNA reverses this resistance (48). More recently,
OVCA429 cells that were transduced with a retroviral vector
expressing NICD3 showed an increase in expression of smooth
muscle actin, Slug and Snail, consistent with an epithelial to
mesenchymal transition. Interestingly, this shift was associated
with an increase in resistance to carboplatin-induced apoptosis
(49). McAuliffe and colleagues (39) suggested that tumorigenic
OvCa stem cell (CSC) populations defined as CD44+ cells or
the side population fraction [reviewed by Foster et al. (50)]
were decreased with inhibition of γ-secretase activity. These
data suggest that Notch signaling may support populations of
CSCs in OvCa that are resistant to conventional cytotoxic ther-
apies. Notch signaling can modulate other signaling pathways
that may influence CSC function. Specifically, the Notch target
Hes1 modulates Gli1 expression and Hedgehog signaling pro-
viding another mechanism of therapeutic resistance (51). Inhi-
bition of Hedgehog signaling has been shown to augment the
effect of P/C as well as delay recurrence of disease in a PDX
model of OvCa (44). Given that Notch signaling may support
CSC activity in OvCa, inhibition of the Notch pathway could
selectively target tumor-initiating populations and act to restore
chemosensitivity. This leads to the hypothesis that Notch pathway
inhibition in OvCa would produce the most robust effects in a
platinum-resistant tumor.
Our investigation suggests a GSI in combination with con-
ventional cytotoxic chemotherapy significantly improves the anti-
tumor effects in primary human OvCa xenografts known to be
clinically resistant to platinum therapy. This extends the previous
findings by McAuliffe and colleagues who demonstrated the effi-
cacy of targeting the Notch pathway in xenografts derived from
established OvCa cell lines (39). While this elegant study demon-
strated GSI induced anti-tumor activity restored chemosensitivity,
it was unclear if primary-derived ovarian tumors would respond
to therapy in vivo in the same fashion. From a clinical perspec-
tive, platinum sensitivity, defined as a >6 month progression-free
interval after platinum-based therapy, is one of the most impor-
tant prognostic factors for women with OvCa (52, 53). In order
to better understand the in vivo response to GSI, we utilized
PDXs derived from women with known platinum-sensitive or
platinum-resistant disease. We observed that single agent MRK-
003 significantly inhibited tumor growth of two of three platinum-
sensitive ovarian tumors, as well as one out of three platinum-
resistant tumors. When we combined GSI with conventional cyto-
toxic therapy, synergistic activity occurred only in the clinically
defined platinum-resistant tumors. These findings support data
showing that inhibition of Notch signaling increases sensitivity
to chemotherapy (32, 39), implying that the Notch pathway is
involved in the development of chemoresistance.
Currently, early phase clinical trials assessing treatment efficacy
of either single agent GSI or monoclonal antibodies focused on
disruption of ligand binding have been conducted in a number of
solid tumors including thyroid, non-small cell lung, desmoids,
and OvCas (54). The overall promising efficacy of disrupting
Notch signaling has been tempered by some adverse events, which
are primarily gastrointestinal (55, 56). In our study, we used the
pan GSI MRK-003 whose clinical analog MK-0752 is in develop-
ment for treatment of several solid malignancies (56). Although
treatment with other GSIs has resulted in toxicity, we did not
observe any excessive weight loss or treatment related death in our
experiments.
The success of targeted therapies inhibiting Notch signaling will
also depend upon the development of biomarkers that can identify
those patients who are most likely to respond (54). Currently, there
is no universal biomarker that indicates Notch family dependence
and is correlated with response to a particular GSI. This objective
may become more complicated given recent evidence that Notch
signaling can serve an oncogenic or tumor suppressor function
depending on the disease context (57). We observed no correlation
between baseline Notch1 or Notch3 protein levels and response
to treatment with MRK-003 alone in any of the ovarian tumors
we analyzed. A marked decrease in Hes1 mRNA expression was
observed in both the platinum-sensitive and platinum-resistant
PDXs following GSI therapy (data not shown), confirming that
this downstream marker of on target effect is also of limited value
for associating anti-tumor effect. Recent work examining the effi-
cacy of MRK-003 in pancreatic cancer xenografts similarly did not
identify a clear biomarker (9).
In conclusion, this pilot investigation suggests specific Notch
family members are variably expressed in OvCa and that MRK-
003-mediated inhibition of Notch signaling reduces OvCa cell
proliferation in vitro and inhibits tumor growth in vivo. While
single agent anti-tumor activity was observed in many of the PDX
analyses, GSI improved conventional cytotoxic therapy exclusively
in combination with paclitaxel in those OvCa tumors known to be
clinically platinum-resistant. Our results support the rationale for
further investigation of the pre-clinical and clinical effectiveness
of GSIs in OvCa, especially in the platinum-resistant setting.
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